

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/63, 15/85, 5/10 C12P 21/00, A61K 48/00	A1	(11) International Publication Number: WO 90/12878 (43) International Publication Date: 1 November 1990 (01.11.90)
(21) International Application Number: PCT/GB90/00604 (22) International Filing Date: 20 April 1990 (20.04.90) (30) Priority data: 8909218.3 22 April 1989 (22.04.89) GB (71) Applicant (for all designated States except US): MEDICAL RESEARCH COUNCIL [GB/GB]; 20 Park Crescent, London WIN 4AL (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : NEUBERGER, Michael, Samuel [GB/GB]; 34 Bateman Street, Cambridge CB2 1NH (GB). MEYER, Kerstin, Barbara [DE/DE]; Alte Berchtesgadener Strasse 15, D-8246 Marktschellenberg (DE).		(74) Agent: KEITH W. NASH & CO.; Pearl Assurance House, 90-92 Regent Street, Cambridge CB2 1DP (GB). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB, GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), US. Published With international search report.
(54) Title: IMPROVEMENTS IN OR RELATING TO ENHANCERS (57) Abstract <p>A novel enhancer, known as the K3'-enhancer, has been identified in the mouse immunoglobulin K locus, downstream of C_K. The K3'-enhancer is B cell specific, is some sevenfold stronger than the K-intron enhancer and the region of the enhancer shows striking sequence homologies to the lymphotropic papovavirus, IgH and K-intron enhancers. The novel enhancer allows high level expression both in transfected cell lines and in transgenic mice, and may thus be used to enhance expression of genes in host cells, <i>in vivo</i> and <i>in vitro</i>. The novel enhancer is also found to increase somatic mutation of antibody genes in transgenic mice. The novel enhancer can also be used in gene therapy. Functionally equivalent enhancers are to be expected to occur downstream of C_K of the immunoglobulin K locus of other species.</p>		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LJ	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

- 1 -

Title: Improvements in or relating to enhancers

Field of invention

This invention relates to enhancers and concerns recombinant DNA molecules comprising a novel enhancer, and use of the enhancer is gene expression and gene therapy.

Background to the invention

Enhancers are DNA sequences which play an important role in the transcription of proteins. A number of different enhancer sequences have been identified from different sources, including enhancers of viral origin, e.g. from the SV40 virus, and of cellular origin. As regards the immunoglobulin (Ig) genes, enhancer elements have been identified in the major introns of both the heavy chain (IgH) (Banerji et al., 1983; Gillies et al., 1983; Neuberger, 1983) and kappa (identified herein as "K") light chain (Picard and Schaffner, 1984; Queen and Stafford, 1984) loci.

The present invention is based on the identification of a novel enhancer in the mouse immunoglobulin K locus, downstream of C_K , in addition to the K-intron enhancer. Functionally equivalent enhancers are to be expected to occur downstream of C_K of the immunoglobulin K locus of other species.

SUBSTITUTE SHEET

- 2 -

Summary of the invention

According to one aspect of the present invention there is provided a recombinant DNA molecule comprising an enhancer having at least part or parts of the base sequence occurring downstream of C_K of the immunoglobulin K locus of any species.

The enhancer located in the mouse K locus occurs in the sequence given in Figure 3A, and the location of the enhancer has been further localised to the sequence given in Figure 12B.

Thus, in a further aspect the invention provides a recombinant DNA molecule comprising an enhancer having at least part or parts of the following base sequence:

AGAAGACCCTTTGAGGAACTGAAAACAGAACCTTAGGCACATCTGTTGC

In another aspect the invention provides a recombinant DNA molecule comprising an enhancer having at least part or parts of the base sequence given in Figure 3A.


The following refers generally to work on the enhancer located in the mouse K locus. It will be apparent to those skilled in the art that functionally equivalent enhancers in other species can be identified by routine investigation.

The novel enhancer is located about 9kb downstream (3') of C_K , and is known as the K3'-enhancer. Like the K-intron enhancer, the K3'-enhancer is also B cell specific. This novel enhancer is some sevenfold stronger than the K-intron enhancer and the region of the enhancer shows striking sequence homologies to the lymphotropic

- 3 -

papovavirus, IgH and K-intron enhancers. The location of the K3'-enhancer between C_K and the RS element means that it is likely to be deleted, at least one allele, in many B cells that express lambda light chains.

The existence of a second enhancer in the mouse K locus explains various previously unexplained observations. For example, locus, transgenes containing all the previously identified K transcription elements were not expressed at high level (Rusconi and Kohler, 1985; Pettersson et al., 1989). Furthermore, the endogenous K gene in the S107 plasmacytoma cell line is well expressed despite the fact that the intron-enhancer is not active in this cell line, which lacks the enhancer binding factor NF-KB (Atchinson and Perry, 1987,1988). The existence of multiple activating sequences in the region of the immunoglobulin loci may also explain why many immunoglobulin transgenes are less transcriptionally active than the endogenous loci; the transgenes may not include the full complement

**SUBSTITUTE SHEET**

- 4 -

of activating sequences. Indeed, we have found only weak transcriptional activity in transgenic mice that harbour a K transgene that extends only 1.2 kb downstream of the C_K exon.

The molecule of the invention may additionally comprise other elements, and will generally further comprise a promoter and gene or genes coding for a protein or proteins of interest. One or more additional enhancers may also be included.

The novel enhancer may be used in any geometrical configuration of DNA arrangement. The enhancer is preferably closer to a promoter than the natural spacing (in a functionally rearranged K gene the enhancer is about 13kb downstream of the promoter), as this is found to give improved levels of gene expression. Expression levels may also be further improved by locating the enhancer close to the protein coding region.

The role of the K3'-enhancer in K gene expression has been examined, and experiments with transgenic mice have shown that the region including the 3'-enhancer is necessary to achieve, and enables achievement of, high level expression of K transgenes. Its omission leads to poor allelic exclusion and a 20-50 fold lower level of K synthesis. Transfection experiments reveal that the 3'-enhancer also acts to give a significant increase in the expression of K genes introduced into cell lines. Deletion mapping of the enhancer localises its activity to a 50 nucleotide region that lacks an NF-KB site: indeed the 3'-enhancer allows K expression in a cell in which lacks NF-KB. Thus this enhancer is necessary for proper K light chain expression and is induced by a pathway distinct from that used for

- 5 -

the intron-enhancer, which is dependent on NF-KB.

The novel enhancer may thus be used to enhance expression of genes in host cells, in vivo and in vitro, particularly in certain lymphoid cell lines and in transgenic animals.

Because the inclusion of the 3'-enhancer in K transgenes dramatically improved the expression of such transgenes, this has important implications for the use of transgenic animals for the production of large amounts of antibody which is encoded by the transgene or for producing a repertoire of human monoclonal antibodies. Further, experiments have shown that the high expression of the transgene also means that expression of endogenous light chain genes is minimised: this fact could also be of use in making a transgenic animal which mainly makes transgenically-encoded antibody.

Work has also been carried out to investigate the role of the novel enhancer in somatic mutation of antibody genes in transgenic mice.

The antigen-binding site of an antibody is formed by the combination of the variable domains of the antibody heavy and light chain. These variable domains are in turn encoded by a combination of gene segments: V_H , D_H and J_H for the heavy-chain and V_L and J_L for the light chain. There are several such segments in the genome. However, a particular antibody-producing B lymphocyte uses a particular combination of V, D and J segments and this ability to choose different combinations contributes to the diversity of the antibody repertoire that an animal can make (combinatorial diversity). However, there is another diversity imposed on top of this due to somatic

SUBSTITUTE SHEET

- 6 -

mutation. A B lymphocyte is able to introduce mutations into the particular rearranged antibody genes that it harbours. In other words, having chosen a specific $V_H D J_H / V_L J_L$ combination, a B cell can (at a later stage) specifically target mutations to these rearranged gene segments. Thus, when the mouse is first immunised, the antigen binds to specific B cells which happen to carry antibodies which have a variable domain which binds the antigen. These B cells now go on to secrete the cognate antibody. However, these activated B cells can also now target a somatic mutation process to their rearranged antibody gene segments and thus allow the production of daughter cells which make variants of the antibodies of the primary response. A selection process now amplifies those variant B cell descendants which make an antibody of improved affinity of the antigen. Thus somatic mutation allows affinity maturation - the production and selection of high affinity antibodies. Therefore, somatic mutation is important for the generation of high affinity antibodies.

The work has demonstrated that transgenes which contain the region downstream of C_K which includes the 3'-enhancer can be somatically mutated; shorter transgenes cannot. Thus, if one is creating a transgenic animal for the purpose of making a repertoire of high affinity human antibodies, it is important that the region spanning the 3'-enhancer be included in the transgene. On the other hand, if the purpose is to make an animal which makes a specific, unique transgenically-encoded antibody, it may be desirable to ensure that the transgene cannot be a target for the somatic mutation process and therefore to avoid the 3'-enhancer.

SUBSTITUTE SHEET

- 7 -

Because the novel enhancer is B cell specific it may be used to target tissue specific expression of genes. This property means the enhancer potentially finds particular use in certain therapeutic applications, for targeting production of proteins, and in hybridoma technology.

The sequence of the novel enhancer may be derived by recombinant DNA techniques from a naturally occurring gene system or may correspond to a naturally occurring gene system in the sense of being manufactured using known techniques of polynucleotide synthesis from sequence data relating to a naturally occurring gene system. Alterations of the sequence may be made which do not alter the function of the enhancer.

The invention also provides a vector for the integration of a gene into the genetic material of a host cell such that the gene may be expressed by the host cell, the vector comprising the gene, a promoter and the novel enhancer.

The term "vector" as used herein connotes in its broadest sense any recombinant DNA material capable of transferring DNA from one cell to another.

The vector may be a single piece of DNA in linear or circular form and may additionally include such other sequences as are necessary for particular applications. For example, the vector may contain additional features such as a selectable marker gene or genes, and/or features which assist translation or other aspects of the production of a cloned product.

The term "gene" as used herein connotes a DNA sequence,

- 8 -

preferably a structural gene encoding a polypeptide. The polypeptide may be a commercially useful polypeptide, such as a pharmaceutical and may be entirely heterologous to the host cell. Alternatively the gene may encode a polypeptide which is deficient, absent or mutated in the host cell.

The host cell may be any host cell susceptible to uptake of the vector of the invention. The vector DNA may be transferred to the host cell by transfection, infection, microinjection, cell fusion, or protoplast fusion.

The host cell may be a cell of living human or animal. In particular, the host cell may be a cell of a transgenic animal such as a mouse. The host cell may be a human stem cell such as bone marrow cell.

The promoter may be any promoter capable of functioning in the host cell and may be for example a mammalian or viral promoter.

The invention also includes within its scope a host cell, e.g. of a cell line or a transgenic animal, transformed with a molecule or vector according to the invention.

The invention further provides a method of producing a polypeptide, comprising culturing a host cell transformed with a molecule or vector according to the invention.

The method may be applied in vitro to produce a desired polypeptide. In addition, the method may be applied in vivo to produce a polypeptide having no therapeutic value to the animal. Such a method of producing a polypeptide is not to be considered as a method of treating the human

SUBSTITUTE SHEET

- 9 -

or animal body.

In a further aspect of the invention the vector or molecule may be used in a method of treatment of the human or animal body by replacing or supplementing a defective gene.

Many diseases of the human or animal body result from deficiencies in the production of certain gene products. The characterising features of the vectors of this invention make them amply suited to the treatment of deficiencies by gene therapy in vivo.

A method of gene therapy is thus provided comprising removing stem cells from the body of a human or an animal, killing stem cells remaining in the body, transforming the removed stem cells with a vector or molecule of the invention containing a gene deficient, or absent, in the human or animal body, and replacing the transformed stem cells in the human or animal body. This method can be used to replace or supplement a gene deficient in a human or animal.

Bone marrow is a suitable source of stem cells and is advantageous in that it contains the precursors of both lymphocytes and erythroid cells. Alternatively other tissue could be removed from the body transfected or otherwise provided with a vector or molecule of the invention and implanted back into the body.

The invention will be further described, by way of illustration, with reference to the accompanying Figures, in which:

SUBSTITUTE SHEET

- 10 -

Figure 1A is a map of the mouse K locus depicting the fragments A to D assayed for enhancer activity;

Figure 1B is a schematic representation of the pbeta800 plasmid used for enhancer assays;

Figure 1C illustrates ribonuclease protection assays of beta- and alpha-globin mRNA in MPC11 cells transfected with either pbeta800 (-) or with derivatives in which either the SV40 enhancer or one of fragments A to D have been cloned in at -800;

Figure 2A is a map showing fragments of fragment D of Figure 1A assayed for enhancer activity;

Figure 2B illustrates the results of ribonuclease protection assay of enhancer activity;

Figure 3A illustrates the base sequence of the SacI-XbaI enhancer fragment identified in Figure 2 and containing the novel K3' enhancer;

Figure 3B indicates sequence homologies, with boxes and lines being used to identify homologies in Figures 3A and 3B;

Figure 4 illustrates cell-type specificity of the K3' enhancer;

Figure 5 illustrates the results of ribonuclease protection assays to compare activity of the K3' enhancer and the K-intron enhancer;

Figure 6A is a Southern blot of various lambda-expressing

SUBSTITUTE SHEET

- 11 -

cell lines;

Figure 6B is a map of the mouse K locus showing the RS element as well as the rearranged RS allele of plasmacytoma MOPC315;

Figure 7 illustrates long and short K gene constructs used to establish transgenic mouse lines;

Figure 8 shows histograms illustrating immunofluorescence analysis of K gene expression in transgenic mice;

Figure 9 illustrates titration of transgenic light chain secreted by of hybridomas from the transgenic mice;

Figures 10A, B and C illustrate expression of K genes transfected into NSO;

Figures 11A, B and C illustrate future delimitation of enhancer activity, with Figure 11A being a map showing the subfragments of the 808bp SacI-XbaI K3'-enhancer that were assayed for activity; Figure 11B being a schematic representation of plasmid pbeta128 used for the enhancer assays; and Figure 11C illustrating the result of a ribonuclease protection assay;

Figures 12A and B illustrates functional deletional analysis of enhancer subfragment f of Figure 11A, with Figure 12A illustrating the results of ribonuclease protection assays using deletions illustrated in Figure 12B;

Figure 13A illustrates the results of ribonuclease protection assay of K transcription in 3 stable

SUBSTITUTE SHEET

- 12 -

transfectants of plasmacytoma S107, illustrated in Figure 13B, showing that the 3' enhancer allows expression of transfected K genes in S107;

Figure 14 illustrates point mutations in the endogenous V region sequences of anti-phOX hybridomas from transgenic mice, with Figure 14A giving details for the oxazolone light chain V regions and Figure 14B giving details for the oxazolone heavy chain V regions;

Figure 15 illustrates nucleotide changes in transgene cDNA clones from anti-phOX hybridomas from transgenic mice; and

Figure 16 illustrates nucleotide changes in transgene cDNA clones from anti-phOX hybridomas from transgenic mice.

Detailed description

An enhancer is located 9 kb downstream of C_K

Experiments were carried out to look for a second enhancer implicated in K gene transcription, located 3' of the J_K segments. The germline V_K genes, at least in man, are scattered over some several thousand kb upstream of J_K; much of the DNA upstream of J_K is deleted in K expressing cell-lines (Klobeck et al., 1987). To test for enhancer activity downstream of C_K, we exploited the fact that the human beta-globin gene in plasmid pbeta800 (Figure 1B) is only a weak transcription unit in transfected cells unless it is provided with an exogenous enhancer element.

Various DNA fragments from the germline mouse K clone L1 (Steinmetz et al., 1979) shown in Figure 1A were assayed for enhancer activity. In this Figure the two K enhancers

SUBSTITUTE SHEET

- 13 -

(K-intron E and K3'E) are indicated and restriction sites are abbreviated as follows: B, BamHI; R, EcoRI. The BamHI fragments A to D of Figure 1A and also the SV40 enhancer (SV) (for comparative purposes) were subcloned into plasmid pbetaG800 (Figure 1B), with the fragments being placed 800 bp upstream of the beta-globin start site. The DNA from the resulting constructs, and also from pbetaG800 containing no enhancer (-) for comparative purposes, was introduced into MPC11 myeloma cells by calcium phosphate coprecipitation along with a human alpha 2-globin plasmid that provided an internal reference. The amount of beta- and alpha-globin mRNA produced by the transfected cells was then measured in ribonuclease protection assays, and the results are given in Figure 1C. In this Figure bands corresponding to correctly initiated beta-globin transcripts are indicated as are the alpha-globin transcripts encoded by the co-transfected reference plasmid.

As can be seen from Figure 1C, little mRNA is produced from the beta-globin gene in the absence of an exogenous enhancer; however, provision of the SV40 enhancer strongly activates transcription. As regards the DNA fragments from the K locus, strong stimulation of beta-globin transcription was found using fragment D but no such stimulation was found using fragments A, B or C. Thus, inclusion of fragment D on the plasmid but at a distance from the beta-globin gene activates transcription from the beta-globin promoter. The existence of a transcription enhancer element within fragment D is deduced, and this enhancer is referred to as the K3'-enhancer to distinguish it from the K-intron enhancer located in the J_K-C_K intron that has been identified previously (Queen and Baltimore, 1983; Picard and Schaffner, 1984; Queen and Stafford,

SUBSTITUTE SHEET

- 14 -

1984).

To delineate the K3'-enhancer element further, assays were made of a number of deletions of fragment D (constructs 1-4 identified in Figure 2A) as well as some individual subfragments (constructs 5-8 identified in Figure 2A). In Figure 2A, restriction sites are abbreviated as in Figure 1A plus the following: Bg, BglII; S, SacI; V, EcoRV; X, XbaI. The bars depict the K locus included in each construct. MPC11 cells were transfected with the alpha 2-globin reference plasmid plus either plasmid pbeta800 containing no enhancer (-) or with derivatives that included at position -800 either the SV40 enhancer (SV) or the K DNA fragments 1 to 4 that are depicted in Figure 2A. Lanes 5 to 8 were obtained by transfection with pbeta128 derivatives in which K DNA fragments were cloned into position -128. (The pbeta128 plasmid is identical to pbeta800 except that it includes 128 bp rather than 800 bp of beta-globin 5' flanking DNA.) The results are given in Figure 2B, with the positions of correctly initiated alpha and beta-globin transcripts indicated.

As shown in Figure 2B, enhancer activity was found in constructs 2, 3, 4, 6 and 7 but not in constructs 1, 5 and 8. This suggests that the enhancer is located within the 0.8 kb SacI-XbaI fragment, a prediction that was confirmed by subcloning this fragment into an enhancerless beta-globin vector (Figure 4). The novel enhancer is located approximately 9kb downstream of C_K.

The K3'-enhancer contains regions homologous to the IgH, K-intron and LPV enhancers

The sequence of this SacI-XbaI fragment was determined and

SUBSTITUTE SHEET

- 15 -

is presented in Figure 3A. In Figure 3B sequence homologies are shown to regions of the IgH, LPV, K-intron and SV40 enhancers as well as to the IFN response element (Samanta et al., 1986; Reid et al., 1989) and the conserved upstream sequence (CUS) of HLA-DQbeta that is implicated in gamma-IFN induction (Boss and Strominger, 1986). The E-boxes marked in the IgH comparison refer to the nomenclature used by Ephrussi et al. (1985). In the comparison of the K3'-enhancer with the E2/3 region of the IgH enhancer, the dashed box shows the extended homology to uE3 and the arrows denote the inverted repeat of the uE2/3 spacer as well as the region that flanks the 3' side of uE3.

Comparison with the sequences of other known enhancers revealed several striking homologies. The most extensive homology detected was with the enhancer region of the human lymphotropic papovavirus. There are two distinct regions of homology, a 17 out of 18 match and an 11 out of 12 match; both these elements are repeated within the origin region of the viral genome (Pawlita et al., 1985).

The other impressive homology is with a region around the E3 element of the IgH enhancer. Motifs (elements E1, E2, E3 and E4) within the IgH enhancer have been identified on the basis of the in vivo footprinting data (Ephrussi et al., 1985). The K3'-enhancer contains a segment showing a 12 out of 14 homology to the region of the IgH enhancer that has been shown to bind NF-uE3 (Sen and Baltimore, 1986; Peterson and Calame, 1987). Furthermore, the regions that flank either side of the E3 element in the IgH enhancer are also found to be present adjacent to the E3-like element of the K3'-enhancer but in a reshuffled form (Figure 3B). Significant homologies are also found

SUBSTITUTE SHEET

- 16 -

between the K-intron and K3'-enhancers. There are three separate 10 out of 11 matches: one overlaps the K-intron E3 element, another overlaps the K-intron E1 and the third homology includes within it a 7 out of 8 match to the octanucleotide element (Parslow et al., 1984; Falkner and Zachau, 1984) that has been identified in V gene promoters. In addition, sequence comparisons reveal an 8 out of 10 match to the NF-KB binding site, a sequence homologous to the consensus for the interferon response element (Samanta et al., 1986; Porter et al., 1988; Reid et al., 1989) and a homology to the conserved upstream sequence of the MHC class II genes, a sequence that may play a role in induction by gamma-IFN (Boss and Strominger, 1986). Several segments that show similarity to regions of the SV40 enhancer are also found (Figure 3B).

The K3'-enhancer is B cell specific

The homologies between the K3'-enhancer and other known enhancers led us to believe that it would be specifically active in lymphoid cells. To test this, assays were made of the activity of the enhancer in two non-lymphoid cell lines (NIH 3T3 and HeLa) as well as in three different lymphoid cell lines (the plasmacytoma MPC11; the B-cell line WEHI231 and the thymoma EL4). Cell-lines were transfected with the alpha-globin reference plasmid along with a pbeta128 derivative that included at position -128 either no enhancer (-), the SV40 enhancer (SV) or the 802 bp SacI-XbaI fragment containing the K3'-enhancer (K3'). mRNA levels were quantitated by ribonuclease protection assays as before. The results are given in Figure 4, which shows that while the SV40 enhancer was active in all these lines, the K3'-enhancer was only active in the

- 17 -

plasmacytoma and B cell lymphoma but not in the fibroblast or T cell lines. In other experiments (not shown), we have found that the enhancer is also inactive in another T cell lymphoma BW5147. Thus, the K3'-enhancer is B cell specific.

The K3'-enhancer is stronger than the K-intron enhancer

The K-intron enhancer is known to be a weak enhancer. The activities of the K3', K-intron, IgH and SV40 enhancers were compared in transient transfection assays in the MPC11 myeloma. MPC11 cells were transfected with the alpha-globin reference plasmid plus either pbeta128 containing no enhancer (-), the SV40 enhancer (SV), the K3' or K-intron enhancer (K3', KIn) at position -128 or with a pbeta800 derivative containing the IgH enhancer at -800 (IgH). Globin transcripts were mapped by ribonuclease protection assays, and the results are given in Figure 5. The results were quantitated by densitometry with each signal being normalized with respect to the alpha-globin mRNA levels. It was found that K3'-enhancer is sevenfold stronger than the K-intron enhancer but some twofold weaker than the SV40 enhancer. Direct comparison between these three enhancers and the IgH enhancer is not possible from these experiments as the IgH enhancer was placed at -800 with respect to the beta-globin start site whereas the other three enhancers were all assayed at -128. Nevertheless the results are consistent with those of Picard and Schaffner (1984) that the K-intron enhancer is some 20-fold weaker than the IgH enhancer and furthermore we clearly establish that the K3' enhancer is nearly an order of magnitude stronger than the K-intron enhancer when assayed in MPC11 cells.

SUBSTITUTE SHEET

- 18 -

The K3'-enhancer is deleted upon RS rearrangement

The location of the K3'-enhancer places it between the C_K exon and the RS (rearranging sequence) element. Figure 6B is a map of the mouse K locus showing the RS element as well as the rearranged RS allele of plasmacytoma MOPC315. The map of this rearranged RS is taken from Durdik et al. (1984). Restriction sites are abbreviated as in other Figures except that S indicates a Sau3AI site, although the only such sites depicted are those that were used to generate the rs0.8 fragment. Cells that express lambda light chains are usually found to have aberrant rearrangements involving the RS element on at least one of their K alleles and this can lead to deletion of C_K (Durdik et al., 1984; Moore et al., 1985). It would be expected that the K3'-enhancer would be deleted in these lines if RS rearrangement occurred by a simple looping-out mechanism. To confirm this, a Southern blot analysis was carried out of various lambda-expressing cell lines. DNA from BALB/c mouse liver, NIH 3T6 fibroblast cells and five mouse lambda-expressing lymphoid cell lines (129, BCL1, HOPC1, MOPC315 and CH-1) probed first for the K3'-enhancer (upper panel) and then reprobed for RS (lower panel). In this reprobing, G indicates the germline RS band of BALB/c whereas X is a cross-hybridising band. The genomic DNA was digested with EcoRI+BamHI and the probe for the K3'-enhancer was an 3 kb EcoRI-BamHI fragment whereas the probe for RS was the rs0.8 probe of Moore et al. (1985). The blot is shown in Figure 6A and revealed that several of the cell lines (HOPC1, BCL-1 and CH-1) retained at least one RS allele in germline configuration and, therefore, as is to be expected, retained at least one copy of the K3'-enhancer. The case of 129 is difficult to interpret as the mouse strain from which this lymphoma

SUBSTITUTE SHEET

- 19 -

derives shows considerable restriction map differences from the BALB/c strain (Stavnezer et al., 1985) and the difference in the sizes of restriction fragments could therefore reflect polymorphism rather than rearrangement. However, the MOPC315 myeloma does not retain an RS allele in germline configuration and has entirely deleted the K3'-enhancer from its genome (Figure 6A, B). The interrupted line in Figure 6B indicates the postulated simple looping out that could have given rise to the MOPC315 RS rearrangement. This strongly suggests that the RS rearrangement is itself responsible for the loss of the enhancer and that RS recombination does indeed lead to enhancer deletion.

High level expression in transgenic mice of K genes that include the 3'-enhancer.

Transgenic mouse lines were established in order to ascertain whether sequences located downstream of C_K affected K gene expression. The transgenes were composed of a mouse V_K gene linked to a rat C_K . The presence of the rat constant region meant that the transgene could be distinguished from the endogenous K at the protein level using anti-rat K antibodies and at the nucleic acid level by a ribonuclease protection assay. The V-region was characteristic of antibodies directed against the hapten phenyl-oxazolone. Two transgenes were used: a long one (LK) which includes both the intron- and 3'-enhancers and a short one (SK) which contains only the intron-enhancer. The two gene constructs are shown in Figure 7. In the Figure sequences of mouse origin are shown thickly stippled, rat sequences are shown thinly stippled and enhancers are in pen boxes. Four lines of transgenic mice which harboured between 2 and 5 copies of the

- 20 -

transgene (SK², SK⁴, LK³ and LK⁶) were used for most of the analyses, although a high-copy (SK⁵) line which carried 30-50 copies of the short K construct was also included for comparison.

Transgene expression of the K gene was analysed by immunofluorescence of splenic B cells from adult transgenic mice. The results are given in Figure 8 which shows histograms depicting the percentaged K⁺ cells in the spleens of the adult transgenic mice that stained for either: transgenic rat K and endogenous mouse (TGK⁺, EK⁺); transgenic K only (TGK⁺, EK⁻) or endogenous K only (TGK⁻, EK⁺). In SK⁴ animals carrying the short K construct, transgene expression was weak as judged by the intensity of the fluorescence and was only detectable in some 5-7% of splenic B cells; nearly all the B cells expressed an endogenous mouse light chain (Figure 8). A similar pattern of expression was found in the SK² mice (not shown). The low level of expression can to some extent be compensated for by a large increase in transgene copy number as in SK⁵ mice a greater proportion of the B cells stained for the transgene (Figure 8).

The results obtained with the long K construct contrast sharply with those obtained with the short one. In the LK³ line, 80-85% of the adult splenic B-cell population expressed only the transgene, with the remaining 10-15% of the B cells coexpressing an endogenous light chain (Figure 8). Transgene expression is even more dominant in the LK⁶ line with about 90% of the splenic B cells expressing only rat CK. Thus expression levels from the long K construct are sufficient to effect allelic exclusion.

The difference between the transgenes is also evident from

SUBSTITUTE SHEET

- 21 -

the titres of serum antibody. ELISA assays reveal that whereas the titre of antibody containing transgenic K chains in adult SK² and SK⁴ mice is about 100 ug/ml, the corresponding titre in the LK mice is some 10-50 fold higher. However, the major contribution of cellular selection in determining the overall in vivo pattern of transgene expression (Pettersson et al., 1989) makes such comparisons of serum titres very crude. We therefore compared transgene expression in hybridomas generated by fusing spleen cells from the transgenic mice with the NSO plasmacytoma. Supernatants of hybridoma cells grown to saturation in DMEM/10% FCS were assayed for rat K determinants. Titres are given as the dilution of supernatant required to react with the sequester 50% of the anti-rat K antibody used in the ELISA. The assays have been carried out several times; in each batch of assays of hybridoma supernatants from the same mouse line, the scatter of individual titres was such that the s.e.m. always amounted to less than 25% of the mean. The results are given in Figure 9. As regards both the LK³ and LK⁶ mice, the pattern of light chain expression in the hybrids paralleled what was observed in the immunofluorescence analysis of the splenic B cells. In other words, over 80% of the hybrids synthesised the transgenic light chain and made no mouse K. In contrast, in the SK⁴ mice we found that an endogenous mouse light chain was co-expressed by over 80% of the transgene⁺ hybrids; the same held true for the SK² mice. Presumably the difference in the results obtained from the analysis of transgene expression in the primary B cells of the SK mice from those obtained from analysis of light chain expression in hybridomas reflects the fact that the expression of the transgene in primary cells is below our level of detection; this low level, however, is increased on fusion. From the results shown

SUBSTITUTE SHEET

- 22 -

in Figure 9 it will be seen that transgene expression in the hybridomas from the LK mice is some 20-50 fold higher than from the SK mice. Thus, the short K transgene is only poorly expressed and is relatively ineffective in mediating feedback inhibition of endogenous light chain gene rearrangement. However, results with the long K construct show that sequences downstream of the constant region have a dramatic effect on increasing K gene expression in transgenic mice and allowing effective allelic exclusion of endogenous K expression.

The 3'-enhancer increases K expression in stably transfected plasmacytoma

It is presumed that the 3'-enhancer is responsible for the increased transcriptional activity of the long as opposed to the short K construct. In order to test this directly, we resorted to stable transfection assays in the NSO plasmacytoma as illustrated in Figure 10.

A series of constructs with and without the 3'-enhancer were generated. The plasmids used are illustrated in Figure 10B. All the constructs are based on the "long" K construct depicted in Figure 7. Plasmid 1 contains the EcoRI-BamHI V_K-C_K segment of the long construct cloned between the EcoRI and BamHI sites of pSV2neo; the BamHI site is located 1.2kb downstream of the C_K polyadenylation site; plasmid 2 was created by digesting plasmid 4 with EcoRV and self-ligation; plasmid 4 is the long construct depicted in Figure 7 cloned into the EcoRI site of pSV2neo; plasmid 5 carries the EcoRI-XhoI V_K-C_K segment of the long construct cloned between the EcoRI and XhoI sites of a pSV2neo-derivative that has XhoI linkers in the BamHI site.

- 23 -

The constructs, 1, 2, 4 and 5 of Figure 10B were transfected into NS0 cells and rat K expression in pools of stable transfectants was measured by ribonuclease protection assays. For each construct, transcripts of the transfected and endogenous K genes were assayed in samples of RNA that were prepared from pools of 12 wells each of which contained multiple clones. The results are shown in Figure 10A. The positions of size markers (a HpaII digest of pBR322) are shown in the lane marked "M". Sterile transcripts from the endogenous, aberrantly rearranged K gene of NS0 cross-hybridised with the probe and served as an internal control.

It is clear that expression from constructs 2 and 4 (which include the 3'-enhancer) was significantly higher than from constructs 1 and 5 (which do not). Thus, the 3'-enhancer makes a difference to K gene expression in stably transfected plasmacytoma. The effect is considerably less than that observed with the transgenic mice. This is scarcely surprising as the K transcription unit in the transfected NS0 is linked to the active neo gene with its adjacent SV40 enhancer; this could compensate to some degree for the lack of the downstream enhancer in constructs 1 and 4.

To ensure that the expression levels seen in ribonuclease protection assays from the mixed populations are not biased due to differential outgrowth of specific clones, we analysed serum titres of rat K chains in individual wells which represent distinct integration events. Expression of the transgenic K chain in supernatants of individual wells of NS0 transfectants is depicted as a histogram in Figure 10C. Cells were grown to saturation

- 24 -

in DMEM/10% FCS. Titres are given as the dilution of the culture supernatant that is required to react with and sequester 50% of the anti-rat K antibody used in the ELISA; the s.e.m. is indicated by error bars. The results reflect those seen with the pools.

Functional dissection of the 3'-enhancer

Thus the 3'-enhancer does indeed appear to play a role in K gene expression. The induction of K transcription in several pre-B cell lines is known to correlate with the activation of the intron enhancer and the translocation of one of its cognate binding factors (NF-KB) into the nucleus (REFS). We have previously noted the presence of a sequence related to the NF-KB binding motif in the region of the 3'-enhancer (Meyer and Neuberger, 1989); further work was therefore carried out to delimit the active part of the 3'-enhancer more precisely and in order to discover whether the activation of the intron- and 3'-enhancers could be induced by a common mechanism.

The 808 base pair SacI-XbaI 3'-enhancer fragment of Figure 3 was subcloned and linked to a human beta-globin gene, which served as reporter gene in transient transfection assays. Figure 11A is a map showing the subfragments a-f of the 808bp SacI-XbaI K3'-enhancer that were assayed for activity. Restriction sites are abbreviated: S, SacI; Sp, SspI; N, NcoI; Bx, BstXI; H, HaeIII and St, StyI. For the latter two enzymes, only relevant sites are shown. The solid boxes represent sequence homologies identified to the IgH-intron and the K-intron enhancers. The plasmid pbeta128 used for the enhancer assays is shown schematically in Figure 11B. The constructs carrying the inserts a-f shown in Figure 11 were transfected into the

- 25 -

MPC11 plasmacytoma along with a human alpha-globin reference plasmid; cytoplasmic RNA was prepared 38-42 hrs after transfection. The amount of beta- and alpha-globin RNAs were measured by ribonuclease protection assays and the results are shown in Figure 11C for the pbeta128 derivatives carrying enhancer subfragments a-f, the SV enhancer (SV) or no enhancer (-) at position -128 of pbeta128.

Comparison of the activities of the various subfragments reveals that full activity was contained with a 145 base pair region (fragment f). Not only does fragment f not include the sequence homologous to the NF-KB binding site, but the homologies that we had previously noted to the E2/E3 region of the mouse IgH intron-enhancer as well as to the interferon consensus are also absent from this region. Thus the activity of the enhancer must be caused by sequence motifs that we had not previously identified on the basis of homology searches. To locate such motifs more precisely, we made a number of approximately 20 base pair deletions within fragment f by site-directed mutagenesis. Internal deletions were made within enhancer subfragment f with the following deletion endpoints using the numbering of Meyer and Neuberger (1989): delta1 deletion (nt 389-411, data not shown); delta2 (nt 416-436); delta3 (nt 437-456); delta4 (nt 457-471) and delta5 (nt 476-489). The deleted DNA was substituted by the sequence CTCGAG. The deletions are illustrated in Figure 12B.

MPC11 cells were transfected with a Bluescript KS+ vector (Stratagene) carrying enhancer subfragment f or its deletion derivatives placed 128 nt upstream of the human beta-globin gene along with an alpha-globin reference

SUBSTITUTE SHEET

- 26 -

plasmid. Globin transcripts were mapped by ribonuclease protection assays and the results given in Figure 12A. Enhancer activity is not impaired by deletions 1 or 2, but deletions 3, 4 and 5 abolish function. Interestingly delta3 spans a sequence (TTTGAGGAA) which shows good homology to a region of the mouse IgH enhancer (TTTGGGGAA) that binds a nuclear factor and is implicated in lymphoid-specific transcriptional activity (Araki et al., 1988).

The 3'-enhancer allows K expression in S107 cells which lack NF-KB

Since the activity of the 3'-enhancer could be located to a region that does not include homology to the NF-KB binding motif, NF-KB is presumably not required for its function. Therefore, the 3'-enhancer might well account for the transcriptional activity of the endogenous K gene of S107, a plasmacytoma cell line which lacks functional NF-KB, does not activate the K-intron enhancer and in which many transfected K genes are silent (Atchinson and Perry, 1987). To test this, we stably transfected S107 cells with 3 constructs illustrated in Figure 13B that carried the rearranged K gene with or without the 3'-enhancer. Expression of the transfected K gene was analysed by ribonuclease protection assays from pools of stable transfectants RNA was prepared from pools of 24 wells. Plasmids 1 and 2 are described above in connection with Figure 10; plasmid 3 was derived from the plasmid 4 by internal deletion using ClaI and XhoI. The assay results are given in Figure 13A.

Whereas constructs 2 and 3 which both carry the 3'-enhancer were transcribed at high levels, the expression of construct 1 is scarcely detectable. To ensure that

SUBSTITUTE SHEET

01

- 27 -

the high levels of transcription seen for construct 2 and 3 were not due to single positive clones having outgrown an otherwise negative population, we assayed individual wells and found that for both these constructs all wells tested were positive for rat C_K with high, but somewhat variable expression levels. In sharp contrast, expression levels of construct 1 were below the levels of detection in all wells tested. These results strongly support the proposal that it is the 3'-enhancer which drives expression of the endogenous K gene of S107 and demonstrates that NF-KB is indeed not required for the activity of this enhancer. Interestingly, the presence of the SV40 enhancer in the vector is not able to compensate for the lack of the 3'-enhancer in construct 1; this is in keeping with the fact that the SV40 enhancer is relatively weak in S107 cells, possibly because its activity in plasmacytoma cells depends considerably upon NF-KB (Atchinson and Perry, 1987).

Materials and methods

DNA and Plasmids

The phase lambda clone L1 (Steinmetz et al., 1979) containing the germline mouse K locus was a gift from H. Zachau and plasmids pbeta128, pbeta800 and piSVHPalpha2 (Treisman, 1985) were from R. Treisman and K. Weston. A pbeta800 derivative with a 1 kb XbaI fragment containing IgH enhancer at -800 and a pbeta128 derivative with the SV40 enhancer at -128 were gifts from K. Weston. A pbeta128 derivative containing a 481 bp Sau3AI fragment spanning the K-intron enhancer at position -128 was a gift from Graham Cook. The plasmid containing the RS probe (rs0.8 of Moore et al., 1985) was provided by E. Selsing.

SUBSTITUTE SHEET

- 28 -

The short K construct used for creating the SK transgenic mice has been previously described (Pettersson et al., 1989). For the creation of the long construct, a rat C_K fragment of the LOU allele (Sheppard and Gutman, 1981) was modified by site directed mutagenesis (Carter et al., 1985) to create HpaI and BglII sites at positions corresponding to those found in mouse C_K (Max. et al., 1981). The 470 nt HpaI-BglII rat C_K fragment was then excised and this fragment ligated in place of the equivalent mouse C_K fragment in a mouse genomic XbaI-BamHI subclone in pUC18. This composite C_K was combined with the rearranged mouse V_K Ox-1 (1.4kb EcoRI-XbaI) to form a 5.2 kb EcoRI-BamHI fragment in a pUC vector with a SmaI site flanking the BamHI. An 8 kb SacI-EcoRI fragment containing mouse genomic DNA downstream of C_K (including the K3'-enhancer) was subcloned into pUV18, excised as a SmaI-EcoRI fragment, and ligated together with the 5.2kb V_K Ox-1/composite- C_K EcoRI-SmaI fragment in the EcoRI site of the vector pSV2neo.

Derivatives of the long construct that differed in the C_K 3'-region were created as described above. For deletion analysis of the 3'-enhancer, deletions within a fragment were generated using a Bluescript KS+ vector; single-stranded DNA was prepared by superinfection with helper virus and site directed mutagenesis carried out as described elsewhere (Carter et al., 1985).

Cell lines, cell culture and DNA transfection

Myelomas HOPC1 (Weigert et al., 1970) and MOPC315 (Eisen et al., 1968) and the CH-1 B cell lymphoma (Lanier et al., 1978) were obtained from the American Type Culture

SUBSTITUTE SHEET

- 29 -

Collection, MD, USA. The BCL1 line was given to us by Ellen Vitetta, 129 by Roberto Sitia, HeLa by Richard Treisman and MPC11 BU4 by B. Wasylyk. The WEHI231, BW5147, NIH 3T3 and EL4 cells were from our lab collection and their origin is as previously described (Mason et al., 1985). All cells were grown in DMEM/10% FCS/50 uM 2-mercaptoethanol except that RPMI medium was used for CH-1, 129 and BCL1. The MPC11, BW5147, HeLa and NIH-3T3 cells were transfected by calcium phosphate coprecipitation (Graham and van der Eb, 1973) using 20 ug of test plasmid and 5 ug of pISVHP2 internal reference. Transfection of WEHI231 and EL4 was achieved by use of DEAE-dextran as previously described (Mason et al., 1985). Cells were harvested 36-42 h after transfection.

Preparation and Analysis of RNA and DNA

Total cytoplasmic RNA was prepared and ribonuclease protection assays (Melton et al., 1984) carried out as previously described (Mason et al., 1985). DNA from mamalian cells for analysis by Southern blotting was prepared by phenol extraction of whole cell lysates made using lithium dodecyl sulphate. For sequencing of the K3'-enhancer, subclones were generated in M13mp18 or M13mp19 and sequenced by the chain termination method of Sanger et al. (1977) except that the extension was catalysed by Sequenase (United States Biochemical Corporation). The region was sequenced on both strands.

Transgenic mice and hybridomas

Derivation of transgenic mice lines carrying the SK construct has been described (Pettersson et al., 1989, Sharpe et al., 1990). Previously these have been referred

SUBSTITUTE SHEET

- 30 -

to as KOx lines, but in this work KOx² is designated SK², KOx⁴ is SK⁴ etc. The LK mice were generated by microinjection of a vector-free EcoRI 13.5 kb fragment into the pronucleus of (C57BL/6 x CBA) female x (C57BL/6 x CBA) male eggs as previously described (Reik et al., 1987). Positive offspring were identified by Southern blot analysis of tail DNA or by serum ELISA and bred with BALB/c mice. Hybridomas were established from adult mice by fusion of spleen cells with the myeloma NSO (Galfre and Milstein, 1981).

Serological assays and immunofluorescence

Transgenic K chains were detected by an ELISA using the mouse anti-rat K monoclonal antibody MARK-1 as previously described (Pettersson et al., 1989). Cytoplasmic immunofluorescence of permeabilised spleen cells attached to slides (Pettersson et al., 1989) was performed using FITC-conjugated OX-20 (Serotec) to detect mouse K; to detect transgenic K, we used biotinylated sheep anti-rat antiserum in the presence of 1% normal mouse serum chain followed by streptavidin conjugated to TEXAS-red (Amersham).

DNA transfection and ribonuclease protection assay

MPC11.BU4 was obtained from B. Wasylyk; S107 (originally from the Salk Cell Bank) and NSO (Clark and Milstein, 1981) from our laboratory culture collection and maintained in Dulbecco's modified Eagle's medium containing 10% foetal calf serum. Stable transfection was achieved by electroporation (Potter et al., 1984); the S107 and NSO transformants were selected 24 h after transfection by resistance to G418 (Gibco) at an initial

- 31 -

concentration of 0.5 mg/ml and this selective concentration increased to 1mg/ml (S107) or 2mg/ml (NSO) 6 days after transfection. MPC11 was transiently transfected by calcium phosphate coprecipitation (Graham and van der Eb, 1973) and total cytoplasmic RNA was prepared by NP40 lysis and subsequent phenol extraction of the cytosolic fraction 38-42 h later. Ribonuclease protection assays (Melton et al. 1984) were carried out as described previously (Mason et al., 1985).

Somatic hypermutation occurs in the long (LK) but not the short (SK) version of an immunoglobulin K light chain transgene

Further experiments were carried out with transgenic mice carrying the short and long constructs described above in connection with Figure 7. The SK series contains the 'short' construct that extends 1kb downstream of the C_K gene, and the LK series contains a 'long' construct that extends 9kb downstream of the C_K gene and includes the mouse K3'-enhancer. The transgene V-region is directed against the hapten 2-phenyl oxazolone (phOX) and in combination with the appropriate endogenous mouse heavy (H) chain produces an anti-phOX antibody. For each construct, transgenic mice which contain a low number of copies of integrated DNA have been analysed to see whether the transgene V-region can undergo somatic hypermutation during the immune response to phOX.

In order to invoke a typical secondary immune response accompanied by somatic hypermutation of antibody genes, adult mice heterozygous for the transgene were immunised intraperitoneally with alum-precipitated phOX coupled to chicken serum albumin (phOX₁₇CSA, 30-100ug) together with

SUBSTITUTE SHEET

- 32 -

10^9 heat-killed *Bordetella pertussis* bacteria and were then boosted after 7 weeks with an intravenous injection of soluble phOX₁₇CSA (30-100 ug). Splenic hybridomas were established by fusion with the NSO plasmacytoma 3 days after boosting. Following the use of an ELISA assay on culture supernatants, antigen-specific B-cell hybridomas were isolated and the sequence of the transgene V-region determined by specific cDNA cloning from transgene mRNA. The cDNA cloning was performed by incubating poly(A)+RNA from the relevant hybridomas with AMV reverse transcriptase, dNTPs and an antisense oligonucleotide which hybridised to the 3'-region of either the rat (transgene) or mouse (endogenous) C_K. Full length cDNA was eluted from a denaturing polyacrylamide gel. The polymerase chain reaction was then used to amplify the first strand material using oligonucleotides that hybridised to the 5'-end of V_KOX and the 3'-end of mouse or rat C_K. Amplified cDNA was cloned into vectors M13mp18 or M13mp19 for subsequent sequencing by the dideoxy method. The sequences of cDNAs derived from both the transgenic K genes and the endogenous mouse antibody genes within the same hybridomas were determined in order to confirm that the hybrids were derived from B-cells in which hypermutation had occurred. Sequences of the expressed V_H segments of the hybridomas were determined by a procedure analogous to that used for V_K.

For the SK mice, two independent lines (SK² and SK⁴) have been analysed in detail. Low levels of expression of this construct in transgenic mice and the corresponding lack of allelic exclusion result in hybridomas which co-express an endogenous mouse light chain in addition to the transgene light chain (see above). In order to assess whether somatic mutation had been active in the phOX-specific B-

SUBSTITUTE SHEET

- 33 -

cells, the sequences of the endogenous mouse H and K chains in several transgenic hybridomas were analysed by cloning of PCR amplified first strand cDNA. Figure 14 shows sequence mutations endogenous light (Figure 14A) and endogenous heavy (Figure 14B) chain V region genes in anti-phOX hybridomas from transgenic mice SK² (NQT3-) or SK⁴ (NQT8-). The top line shows the sequence of the germline V_K-OX1 or the germline V_H-OX1. The amino acid translation is given above. Numbers in bold type indicate amino acids in the complementarity determining regions. Sequences of six individual hybridoma clones are given below, and only the positions exhibiting nucleotide differences with germline genes V_H-OX1 and V_K-OX1 are shown. -, identity with germline sequence; ^, probable identity; 3, probably A; a gap indicates that the nucleotide could not be identified or was not sequenced in this region. Predicted coding changes are indicated. Four hybrids were derived from the SK² line (NQT3 fusion) and three from the SK⁴ line (NQT8 fusion). Six out of the seven hybridomas express the idiotypic V_H-OX1/V_K-OX1 gene combination, while one (NQT8/L1.10) uses a different V_H gene together with a V_K of hybridoma NQ10/4.6.1. The six hybridomas with the V_H-OX1/V_K-OX1 idotype all contain nucleotide changes from germline BALB/c sequences and both coding and non-coding changes are found.

The light chain V region sequences include changes which are typical of somatic mutations seen in the phOX response in BALB/c. For example, the region around amino acids 34 and 36 of the light chain has been identified as a potential mutational 'hotspot' (see Berek and Milstein; 1987). The heavy chain V-regions, including the non-V_H-OX1 sequence from NQT8/L1.10, display the features typical of anti-phOX genes, namely a DJ region 16 amino acids in

SUBSTITUTE SHEET

- 34 -

length of which the first residue of the D is Asp and the third a Gly. Nucleotide changes in the V_H -OX1 V regions include a characteristic Ser to Thr changes at position 31 in CDR1 (see Berek and Milstein; 1987) in NQT3/C13.1, NQT3/H15.6 NQT8/E10.1 and NQT8/L20.4. In summary, all seven hybridomas display evidence of somatic mutations in the endogenous heavy and light chain genes. The frequency of nucleotide changes averages 3 per light chain and 4 per heavy chain.

The transgene sequence in the same phOX-specific hybridomas was determined from cDNA clones generated by PCR amplification of specifically primed first-strand cDNA. As the mice contain two (KOX^2) or four (KOX^4) copies of transgene, and it is not known how many of these are transcribed, 10 to 20 cDNA clone V regions (350 bp each) were sequences from each hybridoma. The corresponding C regions (270bp each) of about half of these clones were also sequences. cDNA sequences were compared to that of the introduced gene. Figure 15 shows nucleotide changes in transgene cDNA clones from anti-phOX hybridomas from transgenic mice SK^2 (NQT3-) or SK^4 (NQT8-). The top line shows the sequence of the transgene V_K -Ox1 V region and the rat C kappa region with amino acid translation given above. Numbers in bold type indicate amino acids in the complementarity determining regions. Sequences of cDNA clones derived from seven hybridomas are given below. Only the codon position which showed nucleotide differences from the transgene are shown. Dashes indicate identity with the original sequence, a gap indicates that the sequence was not determined in this region. cDNA clones which exhibit a nucleotide change are individually numbered; those in which there were no changes at all are grouped together

- 35 -

according to whether the V region only, or both the V and the C region, were sequenced. If a copy of the transgene has mutated, one would expect the same sequence change to be encountered several times in 10-20 cDNA clones. On the other hand, if no somatic mutations have occurred, then the sequences should be identical except for random base changes introduced as cloning errors during the first-strand synthesis and PCR. As none of the nucleotide substitutions in Figure 15 was observed as a repeat, we conclude that they all arose as cloning artefacts. The frequency of nucleotide changes seen in the V domains is similar to that seen in the C domains ($3-6 \times 10^4$ per bp, Figure 15), and this frequency is in the order of the error rates expected for reverse transcriptase and Taq polymerase.

Thus endogenous mouse H and L chain V-regions from seven anti-phOX hybridomas were found to be mutated. However, the transgene V-region from the same hybridomas showed no somatic mutation at all. Thus it would appear that the transgene V_K -OX1 sequence has not been altered by somatic mutation in these hybridomas from either of the two KOX transgenic mouse lines although the somatic mutation process had occurred in these cells.

For the LK mice, several hybridomas have been analysed from the LK³ line in the same way as the SK hybridomas were analysed. High levels of expression of this construct in transgenic mice result in increased allelic exclusion and the majority of anti-phOX hybridomas express solely the transgenic light chain with an endogenous mouse heavy chain (see above). In striking contrast to the SK mice, the first 3 anti-phOX hybridomas analysed from line LK³ all contain sequence changes in the transgene V-

SUBSTITUTE SHEET

- 36 -

region. Figure 16 shows nucleotide changes in transgene cDNA clones from anti-phOX hybridomas (mouse link LK³). cDNA clones were generated by PCR amplification of specifically primed first-strand cDNA. V-region sequences of 10 cDNA clones from each hybridoma are grouped according to the pattern of nucleotide changes. Positions at which a base change was encountered in only one of the 10 sequences have been ignored as these are likely to reflect cloning errors rather than true mutations. Numbering of the transgene V_K-OX1 V-region codons is the same as above. Dashes indicate identity with the original sequence, a gap indicates that the sequence was not determined in this region. No mutations are seen in the corresponding C-regions, consistent with the normal in vivo targeting of somatic mutations to V-regions only. Line LK³ carries about 4 copies of the construct; from the distribution of nucleotide changes, it seems that each copy is mutated independently of the others and at least 2 or 3 of the copies are transcribed.

In conclusion, the presence of the 8kb region of genomic DNA which includes the K3'-enhancer appears to be necessary in vivo both for high expression and for somatic hypermutation of Ig light chain transgenes.

SUBSTITUTE SHEET

- 37 -

References

Araki, K., Maeda, H., Wang, J., Kitamura, D. and Watanabe, T. (1988) Cell 53, 723-730.

Atchinson, M.L. and Perry, R.P. (1987) Cell 48, 121-128.

Atchinson, M.L. and Perry, R.P. (1988) EMBO J. 7, 4213-4220.

Banerji, J., Olson, L. and Schaffner, W. (1983) Cell 33, 729-740.

Berek, C. and Milstein, C. (1987) Immunological Reviews 96, 23.

Boss, J.M. and Strominger, J.L. (1986) Proc. Natl. Acad. Sci. USA 83, 9139-9143.

Carter, P. Bedouelle, H. Waye, M.M.Y. and Winter, G. (1985) Oligonucleotide site-directed mutagenesis in M13, An experimental manual Anglian Biotechnology Limited.

Clarke, M.R., and Milstein, C. (1981) Somatic Cell Genet. 7, 657-

Durdik, J., Moore, M.W. and Selsing, E. (1984) Nature 307, 749-752.

Eisen, H.N., Simms, E.S. and Potter, M. (1968) Biochemistry 7, 4126-4134.

Ephrussi, A., Church, G.M. Tonegawa, S. and Gilbert, W.

- 38 -

(1985) Science 227, 134-140.

Falkner, F.G. and Zachau, H.G. (1984) Nature 310, 71-74.

Galfre, G. and Milstein, C. (1981) Meth. in Enzymol. 73, 3-46.

Gillies, S.D., Morrison, S.L., Oi, V.T. and Tonegawa, S. (1983) Cell 33, 717-729.

Graham, R. and van der Eb, A. (1973) Virology 52, 456-467.

Klobeck, H.-G., Zimmer, F.-J., Combriato, G. and Zachau, H.G. (1987) Nucl. Acids Res. 15, 9655-9665.

Lanier, L.L., Lynes, M. and Haughton, G. (1979) Nature 271, 554-555.

Mason, J.O. Williams, G.T. and Neuberger, M.S. (1985) Cell 41, 479-487

Max, E.B., Maize, J.V.Jr. and Leder, P (1981) J. Biol.Chem 256, 5116

Melton, D.A., Krieg, P.A. Rebagliati, M.R., Maniatis, T., Zinn, K. and Green, M.R. (1984) Nucl. Acids Res. 12, 7035-7056.

Meyer, K.B. and Neuberger, M.S. (1989) EMBO J.8, 1959-1964.

Moore, M.W., Durdik, J., Persiani, D.M. and Selsing, E. (1985) Proc. Natl. Acad. Sci. USA 82, 6211-6215.

SUBSTITUTE SHEET

- 39 -

Neuberger, N.S. (1983) EMBO J.2, 1373-1378.

Parslow, T.G., Blair, D.L., Murphy, W.J. and Granner, D.K. (1984) Proc. Natl. Acad. Sci. USA 81, 2650-2654.

Peterson, C. and Calame, K.L. (1987) Mol. Cell Biol. 7, 4194-4203.

Pettersson, S., Sharpe, M.J., Gilmore, D.R., Surani, M.A. and Neuberger, M.S. (1989) Int. Immunol. 1, 509-516.

Pawlita, M., Clad, A. and zur Hausen, H. (1985) Virology 143, 196-214.

Porter, A.C.G., Chernajovsky, Y., Dale, T.C., Gilbert, C.S., Stark, G.R. and Kerr, I.M. (1988) EMBO J. 7, 85-92.

Picard, D. and Schaffner, W. (1984) Nature 307, 80-82.

Potter, H. Weir, L. and Leder, P. (1984) Proc. Natl. Acad. Sci. USA 81, 7161-7165.

Queen, C. and Baltimore, D. (1983) Cell 33, 741-748.

Queen, C. and Stafford, J. (1984) Mol. Cell Biol. 4, 1042-1049.

Reid, L.E., Brasnett, A.H., Gilbert, C.S., Porter, A.C.G., Gewert, D.R., Stark, G.R. and Kerr, I.M. (1989) Proc. Natl. Acad. Sci. USA 86, 840-844.

Reik, W., Williams, G. Barton, S. Norris, M., Neuberger, M. and Surani, M.A. (1987) Eur. J. Immunol. 17, 465-469.

- 40 -

Rusconi, S. and Kohler, G. (1985) Nature 314, 330-334.

Samanta, H., Engel, D.A., Chao, H.M., Thakur, A., Garcia-Blanco, M.A. and Lengyel, P. (1986) J. Biol. Chem 261.11849-11858.

Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. Natl.Acad. Sci.USA 74, 5463-5467.

Sen, R. and Baltimore D. (1986) Cell 46, 705-715.

Sharpe, M.J., Neuberger, M. Pannell, R.Surani, M.A. Milstein, C. (1990) Eur.J. Immunol. in the press.

Sheppard, H.W. and Gutman, G.A. (1981) Proc. Natl. Acad. Sci. USA 78, 7064-7068.

Steinmetz, M., Zachau, H.G. and Mach, B. (1979) Nucl.Acids Res. 6, 3213-3229.

Stavnezer, J., Sirlin, S. and Abbott, J. (1985) J. Exp. Med. 161, 577-601.

Triesman, R.H. (1985) Cell 42, 889-902.

Wabl, M. and Burrows, P.D. (1984) Proc.Natl. Acad. Sci. USA 81, 2452-2455.

Weigert, M.G., Cesari, I.M., Yonkovitch, S.J. and Cohn, M. (1970) Nature 228, 1045-1047.

- 41 -

Claims

1. A recombinant DNA molecule comprising an enhancer having at least part or parts of the base sequence occurring downstream of C_K of the immunoglobulin K locus of any species.
2. A recombinant DNA molecule comprising an enhancer having at least part or parts of the base sequence:
AGAAGACCCTTTGAGGAACTGAAAACAGAACCTTAGGCACATCTGTTGC
3. A recombinant DNA molecule comprising an enhancer having at least part or parts of the base sequence given in Figure 3A.
4. A molecule according to claim 1, 2 or 3, additionally comprising a promoter and at least one gene coding for a protein of interest.
5. A molecule according to claim 4, wherein the enhancer is closer to the promoter than the natural spacing.
6. A molecule according to claim 4 or 5, further comprising one or more additional enhancers.
7. A host cell, transformed with a molecule according to any one of the preceding claims.
8. A host cell according to claim 7, wherein the cell is of a cell line.
9. A host cell according to claim 8, wherein the cell is of a transgenic animal.

SUBSTITUTE SHEET

- 42 -

10. A method of producing a polypeptide, comprising culturing a host cell transformed with a molecule according to any one of claims 1 to 6.

11. A method of gene therapy comprising removing stem cells from the body of a human or an animal, killing stem cells remaining in the body, transforming the removed stem cells with a molecule according to any one of claims 1 to 6 containing a gene deficient, or absent, in the human or animal body, and replacing the transformed stem cells in the human or animal body.




Fig. 2B




Fig 2A

3/16

001 AGCTCAAAACC AGCTTAGGCT ACACAGAGAA ACTATCTAAA AAATAATTAC TAACTACTTA ATAGGAGATT GGATGTTAAG ATCTGGTCAC TAAGAGGCAG
 101 AATTGAGATT CGAACCAAGTA TTTTCTACCT GGTATGTGTTT AAATTGCAGT AAGGATCTAA GTGTAGATAT ATAATAATAA GATTCTATTG ATCTCTGCAA
 201 CAACAGAGAG TGTTAGATTT GTTTGGAAAA AAATATTATC AGCCAACATC TTCTACCATT TCAGTATAGC ACAGAGTACC CACCCATATC TCCCCACCCA
 301 TCCCCCATAC CAGACTGGTT ATTGATTTTC ATGCTGACTG GCCTGAGAAG ATTAAAAAATA GTAATGCTAC CTTATTGGGA GTGTCCCATG GACCAAGATA
 401 GCAACTGTCA TAGCTACCGT CACACTGCTT TGATCAAGAA GACCCCTTGA GGAAGTGAAA ACAGAACCCT AGGCACATCT GTTGCTTTGG CTCCCATCCT
 501 CCTCCAACAG CCTGGGTGGT GCACCTCCACA CCTTTCAAG TTTCCTAAGC CTCATATACC TGCTCCCTAC CCCAGCACCT GGCCAAGGCT GTATCCAGCA
 601 CTGGGATGAA AATGATACCC CACCTCCATC TTGTTTGATA TTACTCTATC TCAAGCCCCA GGTTAGTCCC CAGTCCCAAT GCTTTTGCAC AGTCAAAACT
 701 CAACTTGGAA TAATCAGTAT CCTTGAAGAG TTCTGATATG GTCACGGGC CCATATACCA TGTAAGACAT GTGGAAAGA TGTTCATGG GSCCCAGACA
 801 CGTTCTAG

Fig. 3A

SUBSTITUTE SHEET

4/16




Fig. 3B

5/16




Fig. 4



SUBSTITUTE SHEET

6 / 16




Fig. 5
SUBSTITUTE SHEET



7/16

*Fig. 6B*




8/16

*Fig. 7*

9/16

*Fig. 8**Fig. 9*

10/16

*Fig. 10A**Fig. 10B**Fig. 10C*

11/16

a b c d e f SV-




Fig. 11A

activity - - + + - +




Fig. 11C




Fig. 11B

deletion:
2 3 4 5




Fig. 12A






Fig. 12B

13/16

*Fig. 13A**Fig. 13B*

SUBSTITUTE SHEET

14/16

Fig. 14

POINT MUTATIONS IN THE ENDOGENOUS V REGION SEQUENCES

A OXAZOLONE LIGHT CHAIN V REGIONS

		POSITION NUMBER												
		29	31	34	36	45	49	51	52	60	85	95		
VK Ox-1	NQT3	S	S	H	Y	K	Y	T	S	A	T	P		
		AGT..AGT..CAC..TAC..TAA..TAT..ACA	TCC..GCT..ACT..CCA											
VK Ox-1	CL3.1	A	T		
	F21.3	A	T		
	G7.3		
	H15.6	I	...		
VK Ox-1	E10.1		
	L20.4		
			

B OXAZOLONE HEAVY CHAIN V REGIONS

		POSITION NUMBER																			
		11	22	31	33	46	49	53	56	58	59	65	67	69	77	78	82C	84	86	90	91
V _H Ox-1	NQT3	L	C	S	G	E	G	A	S	N	Y	S	L	I	N	V	L	T	D	Y	Y
		CTG..TGC..AGC..AGT..GGT..GAG..GGA..GCT..AGC..ANT	TAT..TCC..CTG..ATC..AAC..GTT..CTG..ACT..GAC..TAC																		
	CL3.1	...	-T	-C	-C	T	N	I
	F21.3	-3	-TC	C	-T	-T	H
	G7.3	T	C
	H15.6	-C	S
		-G
	NQT8																				
	E10.1	T	L
		-C	C
	L20.4	-C
	

TRANSGENE SEQUENCE		V REGION [350bp]										C REGION [270 bp]																		
LINE	HYBRIDOMA	CDNA	CLONE NOS	2	11	30	36	33	49	51	68	74	76	90	96	103	109	130	139	142	143	146	150	162	164	169	188	189		
				I	M	V	Y	Q	Y	N	G	T	S	Q	L	K	A	A	F	R	D	V	I	S	T	K	H	K		
				ATT. ATG. GTA. TAC. ATG. TAT. ACA. GGG. ACA. AGC. CAG. CTC. AAG													GCT. GCC. TTC. AGA. GAC. GTC. ATT. AGT. ACT. AAA. CXT. AAG													
α ₂	NQ73/C13.1	CDNA	CLONE NOS	1	
				2 to 7
				8 to 16
				1
				2
				3
				4
NQ73/F21.3	CDNA	CLONE NOS	1		
			2	
			3	
			4	
			5	
			6	
			7 to 16	
NQ73/G7.3	CDNA	CLONE NOS	1		
			2	
			3 to 10	
			11 to 20	
NQ73/H15.6	CDNA	CLONE NOS	1		
			2	
			3	
			4 to 19	
α ₄	NQ78/E10.1	CDNA	CLONE NOS	1								

TOTAL NUMBER OF CHANGES	V REGION : 13 CHANGES IN 48 kb	C REGION : 13 CHANGES IN 22 kb
1	1	1
2	2	2
3	3	3
4	4	4
5	5	5
6	6	6
7	7	7
8	8	8
9	9	9
10	10	10
11	11	11
12	12	12
13	13	13
14	14	14
15	15	15
16	16	16
17	17	17
18	18	18
19	19	19
20	20	20
21	21	21
22	22	22
23	23	23
24	24	24
25	25	25
26	26	26
27	27	27
28	28	28
29	29	29
30	30	30
31	31	31
32	32	32
33	33	33
34	34	34
35	35	35
36	36	36
37	37	37
38	38	38
39	39	39
40	40	40
41	41	41
42	42	42
43	43	43
44	44	44
45	45	45
46	46	46
47	47	47
48	48	48
49	49	49
50	50	50
51	51	51
52	52	52
53	53	53
54	54	54
55	55	55
56	56	56
57	57	57
58	58	58
59	59	59
60	60	60
61	61	61
62	62	62
63	63	63
64	64	64
65	65	65
66	66	66
67	67	67
68	68	68
69	69	69
70	70	70
71	71	71
72	72	72
73	73	73
74	74	74
75	75	75
76	76	76
77	77	77
78	78	78
79	79	79
80	80	80
81	81	81
82	82	82
83	83	83
84	84	84
85	85	85
86	86	86
87	87	87
88	88	88
89	89	89
90	90	90
91	91	91
92	92	92
93	93	93
94	94	94
95	95	95
96	96	96
97	97	97
98	98	98
99	99	99
100	100	100

NUCLEOTIDE CHANGES IN TRANSGENE V-REGIONS OF LINE LK³

16/16

TRANSGENE V-REGION SEQUENCE

Amino acid 9 10 14 26 31 33 36 39 46 75 83 85 92 93 96
 A I S S S M Y K R S A T S S L
 GCA ATC TCT AGC AGT ATG TAC AAG AGA AGC GCT ACT AGT AGT CTC

HYBRIDOMA CDNA CLONE
 #

NQT15/12

1,2,3,8
 6,7,9,10
 4

NQT15/17

1
 2
 3,4
 5,9
 6,7,8
 10

NQT15/20

1,2,3,4,6,7,9,10
 5,8

```


--- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
--- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
--- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
-T- -T- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A-
-T- -T- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A-
-T- -T- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A-
--- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
-T- -T- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A- -A-

```

Fig.16

INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 90/00604

I. CLASSIFICATION F SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : C 12 N 15/63, C 12 N 15/85, C 12 N 5/10, C 12 P 21/00, A 61 K 48/00		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC ⁵	C 12 N, C 12 P	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	Nature, vol. 307, 5 January 1984, Macmillan Journals Ltd, D. Picard et al.: "A lymphocyte- specific enhancer in the mouse immunoglobulin kappa gene", pages 80-82, see the whole article (cited in the application) --	1-10
A	Journal of Experimental Medecine, vol. 164, August 1986, The Rockefeller University Press, U. Storb et al.: "Transgenic mice with mu and kappa genes encoding antiphosphorylcholine antibodies", pages 627-641, see page 637, lines 16-19 --	1-9
./.		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁴ Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
11th July 1990		09. 08. 90
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		 M. SOTEL

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, " with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	<p>The EMBO Journal, vol. 7, no. 3, 1988, IRL Press Limited, (Oxford, GB), P. Krimpenfort et al.: "Transcription of T cell receptor beta-chain genes is controlled by a downstream regulatory element", pages 745-750, see the whole article</p> <p style="text-align: center;">--</p>	1-9
P,X	<p>The EMBO Journal, vol. 8, no. 7, 1989, IRL Press Limited, (Oxford, GB), K.B. Meyer et al.: "The immunoglobulin kappa locus contains a second, stronger B-cell-specific enhancer which is located downstream of the constant region", pages 1959-1964, see the whole article</p> <p>(cited in the application)</p> <p style="text-align: center;">-----</p>	1-10